Biotechnology Innovation Centre, Rhodes University, Makhanda, South Africa.
Anal Methods. 2021 Mar 7;13(9):1191-1203. doi: 10.1039/d0ay01878c. Epub 2021 Feb 19.
Most aptamers targeting cell-expressed antigens are intended for in vivo application, however, these sequences are commonly generated in vitro against synthetic oligopeptide epitopes or recombinant proteins. As these in vitro analogues frequently do not mimic the in vivo target within an endogenous environment, the evolved aptamers are often prone to nonspecific binding. The presence of dead cells and cellular debris further complicate aptamer targeting, due to their high nonspecific affinities to single-stranded DNA. Despite these known limitations, assessment of cell viability and/or the removal of dead cells is rarely applied as part of the methodology during in vivo testing of aptamer binding. Furthermore, the extent and route(s) by which dead cells uptake existing aptamers remains to be determined in the literature. For this purpose, the previously reported aptamer sequences 5TR1, 5TR4, 5TRG2 and S22 - enriched against the MUC1 tumour marker of the mucin glycoprotein family - were used as model sequences to evaluate the influence of cell viability and the presence of nontarget cell-expressed protein on aptamer binding to the MUC1 expressing human cancer cell lines MCF-7, Hs578T, SW480, and SW620. From fluorescence microscopy analysis, all tested aptamers demonstrated extensive nonspecific uptake within the nuclei of dead cells with compromised membrane integrities. Using fluorescent-activated cell sorting (FACS), the inclusion of excess double-stranded DNA as a blocking agent showed no effect on nonspecific aptamer uptake by dead cells. Further nonspecific binding to cell-membrane bound and intracellular protein was evident for each aptamer sequence, as assessed by southwestern blotting and FACS. These factors likely contributed to the ∼120-fold greater binding response of the 5TR1 aptamer to dead MCF-7 cells over equivalent live cell populations. The identification of dead cells and cellular debris using viability stains and the subsequent exclusion of these cells from FACS analysis was identified as an essential requirement for the evaluation of aptamer binding specificity to live cell populations of the cancer cell lines MCF-7, Hs578T and SW480. The research findings stress the importance of dead cell uptake and more comprehensive cell viability screening to validate novel aptamer sequences for diagnostic and therapeutic application.
大多数针对细胞表面抗原的适体都旨在用于体内应用,然而,这些序列通常是在体外针对合成寡肽表位或重组蛋白生成的。由于这些体外类似物通常不能在内源性环境中模拟体内靶标,因此进化而来的适体往往容易发生非特异性结合。由于死细胞和细胞碎片具有很高的单链 DNA 非特异性亲和力,因此它们的存在进一步使适体靶向复杂化。尽管存在这些已知的局限性,但在体内测试适体结合时,很少将细胞活力评估和/或去除死细胞作为方法的一部分。此外,在文献中,死细胞摄取现有的适体的程度和途径仍有待确定。为此,先前报道的适体序列 5TR1、5TR4、5TRG2 和 S22——针对粘蛋白糖蛋白家族的 MUC1 肿瘤标志物富集——被用作模型序列,以评估细胞活力和存在的影响非靶细胞表达的蛋白质对 MUC1 表达的人癌细胞系 MCF-7、Hs578T、SW480 和 SW620 中适体结合的影响。从荧光显微镜分析来看,所有测试的适体都在细胞膜完整性受损的死细胞的核内表现出广泛的非特异性摄取。使用荧光激活细胞分选 (FACS),作为阻断剂的过量双链 DNA 的包含对死细胞中非特异性适体摄取没有影响。通过西南印迹和 FACS 评估,每个适体序列都显示出对细胞膜结合和细胞内蛋白的进一步非特异性结合。这些因素可能导致 5TR1 适体与死 MCF-7 细胞的结合反应比等效活细胞群体高约 120 倍。使用活力染色来鉴定死细胞和细胞碎片,并将这些细胞从 FACS 分析中排除,这被确定是评估适体与 MCF-7、Hs578T 和 SW480 癌细胞系的活细胞群体结合特异性的必要要求。研究结果强调了死细胞摄取和更全面的细胞活力筛选的重要性,以验证新型适体序列在诊断和治疗应用中的适用性。